AstraZeneca Pharma India surrenders marketing authorisation for specific indication of Olaparib Ruchika Sharma15 April 2025 3:46 PM ISTBangalore: AstraZeneca Pharma India Limited has surrendered its marketing authorisation for Olaparib film-coated tablets 100mg and 150mg...
CDSCO Panel Approves AstraZeneca's Protocol Amendment Proposal to Study Capivasertib Plus Abiraterone Dr. Divya Colin18 Feb 2024 6:00 PM ISTNew Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the drug major...
AstraZeneca's Lynparza plus abiraterone approved in Japan for treatment of BRCA-mutated metastatic castration-resistant prostate cancer Ruchika Sharma26 Aug 2023 11:30 AM ISTCambridge: AstraZeneca and MSD’s Lynparza (olaparib) in combination with abiraterone and prednisolone has been approved in Japan for the treatment of...
FDA approves niraparib regimen for BRCA-mutated metastatic castration-resistant prostate cancer Dr. Kamal Kant Kohli12 Aug 2023 10:15 AM ISTThe Food and Drug Administration has approved the fixed dose combination of niraparib and abiraterone acetate (Akeega, Janssen Biotech, Inc.), with...
USFDA nod to AstraZeneca, MSD's Lynparza plus Abiraterone and Prednisone or Prednisolone for BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer Ruchika Sharma2 Jun 2023 3:30 PM ISTRahway: AstraZeneca and Merck, known as MSD outside of the United States and Canada, has announced that LYNPARZA in combination with abiraterone...
USFDA panel backs restricted use of AstraZeneca Prostrate cancer drug Ruchika Sharma29 April 2023 12:30 PM ISTLynparza belongs to a class of drugs called PARP inhibitors, which include Clovis Oncology's Rubraca and GSK Plc's Zejula.
Use of abiraterone or enzalutamide may increase risk of metabolic and cardiac adverse events in prostate cancer Dr Nisanth Puliyath20 July 2022 8:00 PM ISTOlder men with advanced prostate cancer receiving abiraterone or enzalutamide have increased risks for metabolic and cardiovascular adverse events, a...
Common prostate cancer medications may be less safe than previously thought Dr. Kamal Kant Kohli1 Jun 2022 8:00 PM ISTMen taking either of the two most common oral medications for advanced prostate cancer who had also undergone hormone therapy to treat their disease...
Neoadjuvant therapy: An advancement in management of high-risk prostate cancer Dr. Nandita Mohan26 Nov 2020 4:00 PM ISTAccording to recent research, researchers have found out that neoadjuvant therapies maybe promising additions to the multimodal therapeutic...
